Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Patent
1995-02-16
1997-12-23
Ulm, John
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
514 2, 514 8, 514 12, 514885, A61K 3820
Patent
active
057004617
DESCRIPTION:
BRIEF SUMMARY
This invention relates to a method for inhibiting HIV replication in cells of monocyte/macrophage lineage which employs Interleukin-4.
BACKGROUND OF THE INVENTION
Human immunodeficiency virus (HIV) was initially identified as the etiologic agent of the acquired immunodeficiency syndrome (AIDS) in 1983. Much has been learned subsequently about the structure and function of this virus. In addition, HIV has been shown to be harbored by T helper J. Med. 321 (24): 1621 (1989)!. The average time interval between the acquisition of HIV infection and the onset of AIDS is approximately 8 to incubation period suggests that HIV replication is at least partially restricted by host factors.
Mononuclear phagocytes play a prominent role in the pathogenesis of AIDS. These cells are among the first to become infected by HIV. They are also major reservoirs for virus in the central nervous system, lungs and lymph nodes; potential vectors for the spread of virus to different tissues within the infected patient and between individuals; and major regulatory cells that control the pace and intensity of disease progression (IFN) that affect viral replication within the mononuclear phagocyte are likely to be major elements in the establishment of restricted virus growth and the delay of HIV disease.
The fact that macrophages are the major virus reservoir in the central nervous system, the lungs, and lymph nodes suggests that therapies that inhibit viral replication in these particular cells may have a major Immunol. 145: 2669 (1990)!.
Interleukin-4 (IL-4) is a lymphokine that has properties that exemplify many of the characteristics of the set of immune recognition-induced responsible for the production of IgE in mice in response to a variety of stimuli that elicit Ig class switching to the expression of this Ig class described based on its ability to enhance DNA synthesis by purified al., J. Exp. Immunol. 155: 914 (1982)!.
IL-4 has also been shown to act on resting B cells to induce expression of (1984)!, and to enhance the subsequent responsiveness of such cells to (1985); Oliver et al., Proc. Natl Acad. Sci. USA 82: 2465 (1985)!.
Human IL-4 is a glycoprotein that exists in forms having molecular weights between 15,000 and 19,000 daltons. cDNAs encoding both mouse and human al., Proc. Natl. Acad. Sci. USA 83: 5894 (1986)!.
IL-4 has potent effects on T lymphocytes as well as B cells. Resting T J. Exp. Med 165: 157 (1987)!. IL-4 also acts on non-lymphoid hematopoietic cells in a variety of ways. It has been shown to inhibit the growth of J. Exp. Med. 170: 577 (1989)! and to increase their cytotoxic activity for
Present methods for treating HIV infection which involve the use of AZT, ddI and ddC have not proven to be very effective. There thus is a need for better methods for treating HIV infection.
SUMMARY OF THE INVENTION
The present invention fills this need by providing such a method. More particularly, this invention provides a method for treating HIV infection comprising administering to a patient infected with HIV a therapeutically effective amount of IL-4.
BRIEF DESCRIPTION OF THE FIGURE
This invention can be more readily understood by reference to accompanying FIG. 1, which is a graphical representation of the inhibition of HIV replication in monocytes by various doses of IL-4.
DESCRIPTION OF THE INVENTION
All references cited herein are hereby incorporated in their entirety by reference.
The present invention is directed to the treatment of HIV infection and all conditions resulting from such infection, such as AIDS. Conditions that can be treated by the, methods of this invention are defined herein to include states and levels of morbidity manifested by one or more of the following criteria: (1) seropositivity for HIV virus (and/or HIV antibody), or the presence of intracellular virus particles which can be identified within leukocyte cell isolates by microscopic evaluation; (2) chronic lymphadenopathy as commonly understood in the art; (3) blood T-helper cell count <400/mm.sup.3 ; (4) a demonstrable parti
REFERENCES:
patent: 4724232 (1988-02-01), Rideout et al.
patent: 5011829 (1991-04-01), Hirsch et al.
P. Mertz et al. (1996) Cellular Immunology, vol. 173, pp. 252-260.
PCT/US91/05477; Int'l. Pub Date: 20 Feb. 1992; Title: "Interleukin-4 and Interleukin-1.beta. Synergistically Induce VCAM-1"; Inventors:Masinovsky et al.
PCT/EP91/02380; Int'l. Pub. Date: 25 Jun. 1992; Title: "Pharmaceutical Compositions for the Treatment of B-Cell Malignancies"; Inventors: Banchereau et al.
PCT/US91/07234; Int'l. Pub. Date: 16 Apr. 1992; Title: "Synergism of TNF and IL-4"; Inventor:Aggarwal.
PCT/US91/09167; Int'l Pub. Date: 9 Jul. 1992; Title: "Use of IL-4 to Enhance Immune Response to Immunogens in Vaccines", Inventors: Rozhon et al.
PCT/US92/00024; Int'l. Pub. Date: 23 Jul. 1992; Title: "Use of IL-4 to Enhance the Reparative Phase of Wound healing and Repair and to Enhance the healing of Infectd Wounds and The Wounds of Diabetic Animals"; Inventors: Schwarz et al.
H. Schuitemaker et al.; "Viral and Cellular Requirements for Replication of HIV in Primary Monocytes", Abstracts of the VII International Conference on AIDS, Florence, 1991, Jun. 16-21;7(1):100 (abstract No. M.A. 1033).
H. Schuitemaker et al., "Proliferation-dependent HIV-1 Infection of Monocytes Occurs during Differentiation into Macrophages", J. Clin. Invest. vol. 89, Apr. 1992, pp. 1154-1160.
Kazazi et al., 1992, Journal of Gen. Virology 73:941-949.
Poli and Fauci, 1992, Aids Research & Human Retroviruses 8 (2):191-197.
Hays et al., 1992, Aids 6 (3):265-272.
Fahey et al. (1992) Clin. Exp. Immunol. vol. 88, pp. 1-5.
Mosmann et al. (1994) Science vol. 265, pp. 193-194.
Fox et al. Biotechnology (1994) vol. 12, pp. 128.
Dulak Norman C.
Gould James M.
Mertz Prema
Schering Corporation
Ulm John
LandOfFree
Method for inhibiting HIV replication using IL-4 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inhibiting HIV replication using IL-4, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inhibiting HIV replication using IL-4 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1800327